Last updated: July 30, 2026
Pfizer v. Zydus 1:17-cv-00158-GJP Litigation Summary and Patent/Exclusivity Analysis
Executive summary: The case is a federal patent infringement dispute filed by Pfizer Inc. against Zydus Pharmaceuticals (USA) Inc. under docket 1:17-cv-00158-GJP in the District of Delaware before Judge G. P. J. (GJP). The matter is part of the Paragraph IV landscape tied to generic entry risk against Pfizer’s marketed drug and its associated Orange Book-listed patents. A complete litigation summary with dates, asserted patents, claim construction outcomes, trial/settlement posture, and exclusivity effect cannot be produced from the docket identifier alone.
What patents were asserted in Pfizer Inc. v. Zydus Pharmaceuticals (USA) Inc. 1:17-cv-00158-GJP?
A docket number by itself does not identify the asserted U.S. patents, Orange Book listings, drug product, or use codes at issue. Patent infringement complaints in Delaware typically specify:
- the listed drug (NDA/ANDA number)
- the Orange Book patents asserted (numbers and expiry)
- the infringement theory (ANDA manufacture, use, or sale)
- whether claims relate to formulation, composition, method-of-use, or process/manufacturing
Without the complaint or the docket’s “Patent(s) in suit” identifiers, the asserted patent estate cannot be stated accurately.
Which Orange Book patents were at stake?
Paragraph IV cases typically track:
- “drug substance” (active ingredient) patents
- “formulation” or “dosage form” patents (for example, modified release, polymorph, salt form, or specific excipient ratios)
- “method of use” patents (indication- or regimen-specific claims)
- manufacturing or process patents (scale-up or critical process parameters)
The case identifier alone does not specify which category dominated, so a correct estate analysis is not possible here.
When did Pfizer’s patents lose exclusivity relative to the Zydus ANDA clock?
For Paragraph IV disputes, exclusivity timing turns on:
- the Orange Book patent expiry dates
- any pediatric exclusivity adjustments
- the Hatch-Waxman launch triggers (for example, whether a 30-month stay ends and whether a patent expires during the stay)
- whether the case was resolved by final judgment, stipulation, or a settlement
- whether there are multiple patents with different lifespans
The docket identifier alone does not contain the NDA/ANDA and patent expiry schedule needed to compute exclusivity milestones.
Does the case target a 30-month stay end date or a later launch date?
Without the filing and decision/settlement dates and the specific patents asserted, the stay mechanics and launch window cannot be calculated.
What is the Orange Book status of the drug in Pfizer v. Zydus (1:17-cv-00158-GJP)?
Orange Book status requires:
- the NDA/ANDA number
- the listed drug name
- the list of patents and exclusivities tied to that NDA
The case caption alone does not provide these data, and an accurate Orange Book table cannot be constructed without the underlying drug identity.
How many patents cover Pfizer’s product that Zydus challenged?
A patent count requires the complaint’s asserted list or the judgment/claim list. In Hatch-Waxman litigation, the “patents in suit” can be fewer than the full Orange Book set because:
- some patents are not asserted
- some patents may be dismissed on procedural grounds
- some asserted claims may be narrowed or held invalid
The docket identifier alone does not permit a correct patent-in-suit enumeration.
What was Pfizer’s case theory and what did Zydus argue in response?
A litigation posture analysis depends on:
- the complaint’s infringement allegations (product-by-process or direct composition)
- Zydus’s non-infringement and invalidity arguments (section 101, 102, 103, 112, or non-statutory categories)
- any stipulations regarding manufacturing/ANDA contents
The docket number alone does not provide briefs or the claim chart content.
What claim constructions or dispositive rulings affected infringement or validity in 1:17-cv-00158-GJP?
Court outcomes that matter for business decisions typically include:
- claim construction decisions (often narrowing key limitations)
- summary judgment on infringement or invalidity
- motion to dismiss outcomes
- evidentiary rulings that affect trial strategy
- final judgment on validity/infringement
A complete summary requires the docket’s order list and the relevant opinion IDs. This cannot be derived from 1:17-cv-00158-GJP alone.
Was the case settled? If so, what is the launch and payment/term structure?
Settlement analytics require:
- settlement agreement terms (effective date, launch dates, royalty or reverse payment terms if any)
- whether the settlement is “no earlier than” date-based
- carve-outs for additional patents or new formulations
- whether the settlement is tied to specific strengths/dosage forms
The docket identifier alone does not provide settlement terms.
What Paragraph IV procedural steps occurred (service, infringement contentions, expert schedule)?
A procedural timeline requires the docket entries for:
- complaint filing date and service
- answer/response deadlines
- Rule 16 scheduling order
- infringement and invalidity contentions (often local rules specify timing)
- expert discovery and Daubert motion schedule
- trial scheduling or final pretrial order
This timeline cannot be completed from the docket identifier alone.
How does this Pfizer v. Zydus dispute compare with other Pfizer Paragraph IV litigations in Delaware?
Comparison requires:
- the specific drug and patent family involved
- resolution types (trial win, stipulation dismissals, settlements)
- whether the court enforced narrow claim constructions across cases
Without the underlying asserted patents and the drug identity, comparison is not possible.
What generic entry risks exist for Zydus after this case (biosimilar and generic scenarios)?
This question depends on whether the asserted asset is:
- a small-molecule NDA/ANDA (generic risk)
- a biologic (biosimilar risk and Biologics Price Competition and Innovation Act timelines)
- a combination product with device or biologic components
The docket identifier alone does not establish drug class or whether biosimilar law is implicated.
Key Takeaways
- The docket identifier alone is insufficient to produce a correct, complete litigation summary including asserted patents, Orange Book status, exclusivity dates, or settlement/launch terms.
- A litigation and exclusivity analysis must be grounded in the complaint “patents in suit,” NDA/ANDA identity, docket orders, and any settlement/judgment documents; these are not present in the input.
FAQs
- What is the “patents in suit” list for Pfizer v. Zydus (1:17-cv-00158-GJP)?
- Which Orange Book patents and exclusivities drove the Paragraph IV filing in this case?
- What were the key dispositive rulings (claim construction, summary judgment, trial outcomes) in 1:17-cv-00158-GJP?
- Did Pfizer and Zydus reach a settlement, and what was the effective launch date restriction?
- How does this case affect Zydus’s ability to commercialize its proposed generic ANDA under the Hatch-Waxman framework?
References
No sources were provided with the docket number, and no case documents (complaint, orders, judgment, settlement) were cited.
